CN117083282B - 可用作hiv整合酶抑制剂的四环杂环化合物 - Google Patents

可用作hiv整合酶抑制剂的四环杂环化合物

Info

Publication number
CN117083282B
CN117083282B CN202280022034.3A CN202280022034A CN117083282B CN 117083282 B CN117083282 B CN 117083282B CN 202280022034 A CN202280022034 A CN 202280022034A CN 117083282 B CN117083282 B CN 117083282B
Authority
CN
China
Prior art keywords
compound
hiv
pharmaceutically acceptable
aids
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280022034.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN117083282A (zh
Inventor
T·J·浩亭
J·A·麦考利
于涛
张永连
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Merck Sharp & Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme BV filed Critical Merck Sharp & Dohme BV
Publication of CN117083282A publication Critical patent/CN117083282A/zh
Application granted granted Critical
Publication of CN117083282B publication Critical patent/CN117083282B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN202280022034.3A 2021-02-16 2022-02-14 可用作hiv整合酶抑制剂的四环杂环化合物 Active CN117083282B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
US63/149927 2021-02-16
PCT/US2022/016261 WO2022177840A1 (en) 2021-02-16 2022-02-14 Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
CN117083282A CN117083282A (zh) 2023-11-17
CN117083282B true CN117083282B (zh) 2026-05-29

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022034.3A Active CN117083282B (zh) 2021-02-16 2022-02-14 可用作hiv整合酶抑制剂的四环杂环化合物

Country Status (12)

Country Link
US (1) US11958864B2 (cg-RX-API-DMAC7.html)
EP (1) EP4294813B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507788A (cg-RX-API-DMAC7.html)
KR (1) KR20230147131A (cg-RX-API-DMAC7.html)
CN (1) CN117083282B (cg-RX-API-DMAC7.html)
AR (1) AR124868A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022223241B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208396A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048138T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009445A (cg-RX-API-DMAC7.html)
TW (1) TW202246286A (cg-RX-API-DMAC7.html)
WO (1) WO2022177840A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024226485A1 (en) * 2023-04-28 2024-10-31 Merck Sharp & Dohme Llc Delivery devices for anti-hiv compounds
WO2026101812A1 (en) * 2024-11-07 2026-05-15 Merck Sharp & Dohme Llc Hiv integrase inhibitors for treatment of hiv infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214142A (zh) * 2016-12-02 2019-09-06 默沙东公司 可用作hiv整合酶抑制剂的四环杂环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
LT2620436T (lt) * 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2018140368A1 (en) * 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214142A (zh) * 2016-12-02 2019-09-06 默沙东公司 可用作hiv整合酶抑制剂的四环杂环化合物

Also Published As

Publication number Publication date
WO2022177840A1 (en) 2022-08-25
CN117083282A (zh) 2023-11-17
ES3048138T3 (en) 2025-12-09
JP2024507788A (ja) 2024-02-21
KR20230147131A (ko) 2023-10-20
CA3208396A1 (en) 2022-08-25
AR124868A1 (es) 2023-05-10
US11958864B2 (en) 2024-04-16
EP4294813A1 (en) 2023-12-27
AU2022223241B2 (en) 2026-04-30
US20220259227A1 (en) 2022-08-18
AU2022223241A1 (en) 2023-08-24
MX2023009445A (es) 2023-08-25
TW202246286A (zh) 2022-12-01
EP4294813B1 (en) 2025-09-10

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant